Oppenheimer Maintains Outperform on ResMed, Lowers Price Target to $175
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Suraj Kalia maintains an Outperform rating on ResMed (NYSE:RMD) but has lowered the price target from $275 to $175.
October 16, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ResMed's price target has been lowered from $275 to $175 by Oppenheimer, although the Outperform rating is maintained.
The lowering of the price target by Oppenheimer could lead to a negative sentiment among investors, potentially causing a short-term decrease in ResMed's stock price. However, the maintained Outperform rating indicates that the analyst still sees potential in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100